GH-Axis Peptides: What Clinicians Need to Know About the Self-Administration Boom
A comprehensive review maps the science and risks of unregulated GH-IGF-1 peptides flooding fitness communities worldwide.
Summary
Unregulated peptides targeting the growth hormone–IGF-1 axis — including GHRH analogs, ghrelin mimetics, and IGF-1 analogs — are increasingly self-administered by fitness-oriented adults seeking fat loss, muscle gain, and recovery benefits. This narrative review from Poznan University of Medical Sciences catalogs the most commonly used agents (sermorelin, CJC-1295, tesamorelin, GHRP-2, GHRP-6, ipamorelin, hexarelin, AOD9604, IGF-1 LR3, PEG-MGF), stratifies them by quality of evidence, summarizes known pharmacology, contrasts clinical data with online self-dosing protocols, and proposes a clinical assessment algorithm. The review finds that most compounds lack robust human safety data, that perceived benefits often exceed what controlled trials support, and that adverse effects — including hormonal disruption, fluid retention, dysglycemia, and theoretical cancer risk — present real clinical challenges.
Detailed Summary
The off-label use of peptide-based performance-enhancing drugs (PEDs) targeting the GH–IGF-1 axis has grown substantially alongside the rise of incretin-based therapies such as GLP-1 agonists, which have normalized injectable peptides in the public consciousness. Against this backdrop, a multidisciplinary team from Poznan University of Medical Sciences conducted a comprehensive narrative review of the most commonly self-administered GH-axis peptides, drawing on PubMed, Google Scholar, Cochrane Library, and structured searches of gray-literature sources including Reddit forums, commercial peptide websites, and bodybuilding blogs. The review covers publications from January 1989 to January 2026 and is organized around four peptide classes: GHRH analogs, GH secretagogues (GHS/GHRPs), the GH fragment AOD9604, and IGF-1 analogs.
The pharmacologic landscape is strikingly uneven. Tesamorelin — a GHRH analog — stands at the top of the evidence hierarchy as the only compound with FDA approval (for HIV-associated lipodystrophy), supported by randomized controlled trials demonstrating statistically significant visceral fat reduction and IGF-1 elevation. Sermorelin and CJC-1295 (with and without Drug Affinity Complex) have phase I/II pharmacokinetic data showing dose-dependent GH and IGF-1 rises, with CJC-1295 DAC producing sustained IGF-1 elevations for up to 14 days per injection — a half-life extension achieved via covalent albumin binding. In contrast, ghrelin receptor agonists such as GHRP-2, GHRP-6, hexarelin, and ipamorelin have modest human trial data and exert off-target effects: GHRP-2 and GHRP-6 elevate prolactin and cortisol, GHRP-6 stimulates appetite via ghrelin-receptor binding, and hexarelin shows cardiac receptor activity in preclinical models. Ipamorelin is the most selective GHRHR agonist reviewed, with minimal prolactin/cortisol elevation, making it popular in self-administration communities despite limited long-term safety data.
AOD9604 — a synthetic fragment of hGH (amino acids 176–191) — is promoted online for fat loss based on in vitro lipolytic effects, yet the only human trial found no significant weight reduction compared to placebo, and the compound did not alter IGF-1 or insulin levels. IGF-1 analogs, particularly IGF-1 Long R3 (IGF-1 LR3) and PEGylated mechano growth factor (PEG-MGF), have essentially no controlled human data beyond pharmacokinetic characterizations; their use is based almost entirely on preclinical models and extrapolation from rhIGF-1 trials in GH-insensitivity syndromes. The review explicitly notes that the anabolic signal of IGF-1 (via IRS-1 → PI3K → Akt → mTOR) is well characterized mechanistically, but translating this to meaningful physique outcomes in healthy, trained adults without clinical deficiency remains unproven.
Adverse effects catalogued across all compound classes include fluid retention and edema (reflecting GH-mediated sodium and water retention), musculoskeletal symptoms including arthralgia and myalgia, injection-site reactions, carpal tunnel syndrome, dysglycemia including insulin resistance and impaired glucose tolerance — particularly with supraphysiologic IGF-1 elevation — and elevation of prolactin and cortisol with non-selective GHRPs. A recurring and clinically serious concern is the mitogenic potential of sustained IGF-1 elevation: IGF-1R signaling suppresses apoptosis and activates proliferative pathways, raising theoretical oncologic risk that cannot be dismissed even though no long-term human data yet confirm it. The review also highlights that compound stacking (combining multiple peptides, often with AAS or other PEDs) is common in self-administration communities, creating compounded and unpredictable risk profiles.
The authors propose a three-domain clinical assessment algorithm for physicians encountering patients using these compounds: (1) structured exposure history covering compound identity, dose, frequency, route, duration, and stacking; (2) symptom-domain triage mapping presenting complaints to known adverse-effect profiles of each agent class; and (3) risk communication that neither legitimizes off-label use nor dismisses the patient. They stratify compounds into four evidence tiers — from FDA-approved randomized trial data (tesamorelin) down to complete absence of human studies (PEG-MGF) — to help clinicians calibrate concern and counseling. The review concludes that the gap between clinical evidence and self-administration beliefs is wide, and that endocrinologists are increasingly the physicians most likely to encounter these patients.
Key Findings
- Tesamorelin is the only GH-axis peptide with FDA approval and RCT evidence, demonstrating significant visceral fat reduction and IGF-1 elevation in HIV-associated lipodystrophy trials.
- CJC-1295 with DAC produces sustained IGF-1 elevations lasting up to 14 days per injection due to covalent albumin binding, contrasting with the short half-life of native GHRH (~7 minutes).
- AOD9604 (hGH fragment 176–191), widely promoted for fat loss, showed no statistically significant weight reduction versus placebo in the only human clinical trial, with no effect on IGF-1 or insulin.
- GHRP-2 and GHRP-6 elevate both prolactin and cortisol in human pharmacokinetic studies; GHRP-6 additionally stimulates appetite via ghrelin-receptor cross-reactivity, contrary to its fat-loss marketing.
- IGF-1 LR3 and PEG-MGF have essentially no controlled human safety or efficacy data — their use in online communities is based entirely on preclinical models and extrapolation.
- A 2023 survey across eight European countries found a 10.4% prevalence of OTC performance-enhancing substance use, illustrating the scale of unregulated self-administration.
- Meta-analyses confirm that recombinant GH increases lean body mass in healthy adults primarily through extracellular fluid retention, not muscle hypertrophy, with no reliable gains in strength or aerobic power.
Methodology
This is a narrative review (not a systematic review or meta-analysis) covering PubMed, Google Scholar, and Cochrane Library publications from January 1989 to January 2026, restricted to English-language sources. Compounds were included if they met at least one criterion: existing peer-reviewed human PK/PD or clinical data, repeated identification in gray literature as commonly self-administered, or sufficient regulatory/pharmacologic relevance to clinical practice. Gray-literature sources (Reddit, commercial peptide sites, bodybuilding blogs) were searched with structured compound-specific queries and treated as anthropological documentation of self-administration behavior, not as evidence of efficacy or safety. No formal risk-of-bias scoring or GRADE framework was applied; the authors self-assessed compliance with the SANRA narrative-review quality tool.
Study Limitations
As a narrative rather than systematic review, the synthesis is subject to selection bias in source inclusion and cannot produce pooled effect estimates. Most included compounds have very small trial populations, short study durations, and no long-term safety follow-up, making definitive conclusions about risk — especially cancer risk — impossible. No external funding was received for the research, though the article processing charge was partially covered by a university foundation; no conflicts of interest were declared by the authors.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: